(Q34265413)

1 August 2017

1 reference

title

Venlafaxine: a 2003 update (English)

1 reference

1 August 2017

Mary A Gutierrez

1

1 reference

PubMed ID

14512125

1 August 2017

Glen L Stimmel

series ordinal

2

1 reference

PubMed ID

14512125

1 August 2017

Janet Y Aiso

series ordinal

3

1 reference

1 August 2017

1 August 2003

1 reference

1 August 2017

Clinical Therapeutics

1 reference

1 August 2017

25

1 reference

1 August 2017

2138-2154

1 reference

1 August 2017

8

1 reference

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Optimizing antidepressant treatment: efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Evidence of the dual mechanisms of action of venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Dual monoamine modulation for improved treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy of SSRIs and Newer Antidepressants in Severe Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Residual symptoms after partial remission: an important outcome in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Effects of cognitive therapy on psychological symptoms and social functioning in residual depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy of Venlafaxine and Predictors of Response in a Prospective Open-Label Study of Patients With Treatment-Resistant Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Sustained response to open-label venlafaxine in drug-resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Generalised anxiety disorder: treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

An overview of generalized anxiety disorder: disease state--appropriate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Treatment of neuropathic pain with venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine for the treatment of chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Venlafaxine-induced serotonin syndrome with relapse following amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Serotonin Syndrome Induced by Low-Dose Venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Antidepressant discontinuation syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Effects of psychotropic drugs on seizure threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Antidepressants, old and new. A review of their adverse effects and toxicity in overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980210-2

7 January 2021

10.1016/S0149-2918(03)80210-2

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

14512125